EP Patent

EP3694604A1 — Methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy

Assigned to Janssen Oncology Inc · Expires 2020-08-19 · 6y expired

What this patent protects

Disclosed are methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy.

USPTO Abstract

Disclosed are methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy.

Drugs covered by this patent

Patent Metadata

Patent number
EP3694604A1
Jurisdiction
EP
Classification
—
Expires
2020-08-19
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.